Skip to Main Content

Paper Details

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
J Immunother Cancer
18
2022
Author NameAffiliation
Louis LacombeCHU de Quebec-Universite Laval
Fred SaadCentre Hospitalier de l'Universite de Montreal/CHUM
Xuya Wang
Russell K PachynskiWashington University School of Medicine
  • 1 - 4

Datasets

Release 1.2